1. 上海中医药大学附属曙光医院肝病科,上海,201203
扫 描 看 全 文
李运东, 高月求, 吴眉, 等. 健脾磨积解毒方联合常规西药治疗代偿期丙型肝炎肝硬化的临床研究[J]. 上海中医药杂志, 2018,52(7):48-51.
LI Yundong, GAO Yueqiu, WU Mei, et al. Clinical study of Jianpi Moji Jiedu Decoction combined with routine western medicine in the treatment of hepatitis C cirrhosis in compensatory stage[J]. Shanghai Journal of Traditional Chinese Medicine, 2018,52(7):48-51.
李运东, 高月求, 吴眉, 等. 健脾磨积解毒方联合常规西药治疗代偿期丙型肝炎肝硬化的临床研究[J]. 上海中医药杂志, 2018,52(7):48-51. DOI: 10.16305/j.1007-1334.2018.07.013.
LI Yundong, GAO Yueqiu, WU Mei, et al. Clinical study of Jianpi Moji Jiedu Decoction combined with routine western medicine in the treatment of hepatitis C cirrhosis in compensatory stage[J]. Shanghai Journal of Traditional Chinese Medicine, 2018,52(7):48-51. DOI: 10.16305/j.1007-1334.2018.07.013.
目的:观察健脾磨积解毒方联合常规西药治疗代偿期丙型肝炎肝硬化的疗效。 方法:将66例代偿期丙型肝炎肝硬化患者随机分为对照组和治疗组,每组33例。对照组予常规西药治疗,治疗组在此基础上加用健脾磨积解毒方。两组疗程均为48周,比较肝功能、Child-Pugh评分、病毒学应答效果、血清肝纤维化指标、肝脏硬度值及肝脏B超积分的变化情况。 结果:①治疗组早期应答率、治疗结束时应答率及持续应答率均高于对照组,差异有统计学意义(P<0.05)。②治疗前后组内比较,治疗组ALT、AST、TBIL水平及Child-Pugh评分均较治疗前降低(P<0.05),ALB较治疗前升高(P<0.05),对照组仅ALT、AST水平较治疗前降低(P<0.05);组间治疗后比较,肝功能指标及Child-Pugh评分差异有统计学意义(P<0.05)。③治疗前后组内比较,两组HA、LN、PCⅢ、Ⅳ-C、肝脏硬度值、肝脏积分、B超积分均较治疗前降低(P<0.05);组间治疗后比较,血清肝纤维化指标、肝脏硬度值、肝脏积分、B超积分差异有统计学意义(P<0.05)。 结论:健脾磨积解毒方联合常规西药治疗代偿期丙型肝炎肝硬化,能有效提高抗病毒疗效,改善患者肝功能,抑制肝纤维化进程。
Objective:To observe the efficacy of Jianpi Moji Jiedu Decoction combined with routine western medicine in the treatment of hepatitis C cirrhosis in compensatory stage. Methods66 patients with hepatitis C cirrhosis in compensatory stage were randomly divided into the control group and treatment group,33 cases in each group. The control group was treated with routine western medicine,and the treatment group was treated with Jianpi Moji Jiedu Decoction based on the treatment for the control group,with a course of 48 weeks. The changes on liver function indexes,Child-Pugh score,virological response,serum liver fibrosis indexes,liver stiffness measurement value and score of liver B-mode ultrasound were compared. Results:①The response rate in the early stage and at the end of the treatment and the sustained response rate in the treatment group were higher than those in the control group,with statistically significant differences(P<0.05). ②Compared with treatment before,the levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL) and Child-Pugh score were decreased(P<0.05) while the albumin(ALB) level was increased(P<0.05) in the treatment group after treatment. Only the ALT and AST levels were decreased in the control group after treatment(P<0.05). After treatment,there were statistically significant differences on the liver function indexes and Child-Pugh score between the two groups(P<0.05). ③Compared with treatment before,the levels of hyaluronic acid(HA),laminin(LN),procollagen type III(PCIII) and collagen type IV(Ⅳ-C),the liver stiffness measurement value,the liver score and the B-mode ultrasound score were decreased in both groups after treatment(P<0.05). After treatment,there were statistically significant differences on serum liver fibrosis indexes,liver stiffness measurement value,liver score and B-mode ultrasound score between the two groups(P<0.05). Conclusion:Jianpi Moji Jiedu Decoction combined with routine western medicine in the treatment of hepatitis C cirrhosis in compensatory stage can effectively improve the antiviral efficacy,ameliorate the liver function of patients and inhibit the hepatic fibrosis process.
代偿期丙型肝炎肝硬化健脾磨积解毒方肝纤维化病毒学应答率肝脏积分
hepatitis C cirrhosis in compensatory stageJianpi Moji Jiedu Decoctionliver fibrosisvirological response rateliver score
0
浏览量
98
下载量
0
CSCD
4
CNKI被引量
关联资源
相关文章
相关作者
相关机构